<DOC>
	<DOCNO>NCT00502307</DOCNO>
	<brief_summary>This phase 2 trial evaluate antineoplastic activity tivozanib ( AV-951 ) treat patient recurrent metastatic renal cell cancer . Tivozanib ( AV-951 ) VEGF-receptor tyrosine kinase inhibitor , may stop growth tumor cell block blood flow tumor .</brief_summary>
	<brief_title>A Study Tivozanib ( AV-951 ) , Oral VEGF Receptor Tyrosine Kinase Inhibitor , Treatment Renal Cell Carcinoma</brief_title>
	<detailed_description>Approximately 200 patient enroled initial , 16 week , open-label period use 1.5 mg/day dose . Patients receive tivozanib ( AV-951 ) continuously 3 week follow 1 week study drug . Patients undergo disease assessment baseline Cycles 2 4 response determine RESIST criterion . After initial , 16 week open-label period , disease status assess compare baseline use modify RECIST criterion : - Patients great equal 25 % tumor shrinkage continue current dose tivozanib ( AV-951 ) - Patients le 25 % tumor change ( growth shrinkage ) randomly assign double-blind tivozanib ( AV-951 ) match placebo 12 week - Patients great equal 25 % tumor growth discontinue</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>≥ 18 year old male females Patients recurrent metastatic renal cell carcinoma ( RCC ) primary RCC amendable surgical intervention Histologically cytologically confirm renal cell carcinoma Measurable disease No one prior systemic treatment ( chemotherapy immunotherapy ) RCC . No active brain metastasis Karnofsky performance status ≥ 70 % , life expectancy ≥ 3 month No childbearing potential , use effective contraception study 4 week last dose study drug Archival paraffin embed tumor tissue , available . Ability give write informed consent Pregnant lactate woman Primary CNS malignancy ; active CNS metastases Hematologic malignancy ( include : leukemia , form ; lymphoma ; multiple myeloma ) Any follow hematologic abnormality : Hemoglobin ≤ 9.0 g/dL ANC &lt; 1500 per mm3 Platelet count &lt; 100,000 per mm3 Any follow serum chemistry abnormality : Total bilirubin &gt; 1.5 × ULN AST ALT ≥ 2.5 × ULN Serum albumin &lt; 3.0 g/dL Creatinine &gt; 1.7 × ULN ( calculate CLCR &lt; 50 mL/min/1.73 m2 ) Proteinuria &gt; 2.5 g/24 hour 4+ urine dipstick Significant cardiovascular disease , include : Active clinically symptomatic leave ventricular failure Active HTN ( diastolic blood pressure &gt; 100 mmHg ) . Patients history hypertension must stable dos antihypertensive drug ≥ 4 week Uncontrolled hypertension : Blood pressure &gt; 140/90 mmHg 2 antihypertensive medication . Myocardial infarction within 3 month prior administration first study dose Unhealed wound ( include active gastric ulcer ) Serious/active infection ; infection require parenteral antibiotic Inadequate recovery prior antineoplastic therapy Inadequate recovery prior surgical procedure ; major surgical procedure within 4 week prior study entry Lifethreatening illness organ system dysfunction compromise safety evaluation Psychiatric disorder , alter mental status precluding inform consent necessary test Inability comply protocol requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>AV-951</keyword>
	<keyword>tivozanib</keyword>
</DOC>